SCHEMBL4604428

SCHEMBL4604428

Cc1cc(-c2ccc(F)cc2)cc(OCCCN2CCCCC2)n1

nearest known ligand 0.61

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.55
HRH3 Q9Y5N1 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6589507 0.99 KCNH2 (0.54) KCNH2HRH3
Hydrochloric Acid SCHEMBL6593290 0.95 HRH3 (0.53) KCNH2HRH3
SCHEMBL4604407 0.95 HRH3 (0.56) KCNH2HRH3
Hydrochloric Acid SCHEMBL5430031 0.94 HRH3 (0.55) KCNH2HRH3
Hydrochloric Acid SCHEMBL6587089 0.87 KCNH2 (0.63) KCNH2
SCHEMBL4604034 0.85 KCNH2 (0.60) KCNH2
Hydrochloric Acid SCHEMBL6588094 0.84 KCNH2 (0.59) KCNH2
Hydrochloric Acid SCHEMBL6589557 0.83 KCNH2 (0.58) KCNH2HRH3
Hydrochloric Acid SCHEMBL7901275 0.82 HRH3 (0.54) KCNH2HRH3
Hydrochloric Acid SCHEMBL7899689 0.81 HRH3 (0.56) KCNH2HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1941879-A1 Neuroprotective agent for the treatment of neuronal damage PAION Deutschland GmbH (DE) 2008-07-09 EP claimed
US-20070021451-A1 Method for preventing or treating neurologic damage after spinal cord injury HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE (JP) 2007-01-25 US claimed
EP-0781766-B1 HETEROCYCLIC DERIVATIVE AND MEDICINE NIPPON SHINYAKU CO LTD (JP) 2004-03-31 EP claimed
US-6191149-B1 DRUG FOR CEREBROVASCULAR DISEASE NIPPON SHINYAKU, CO., LTD. (JP) 2001-02-20 US claimed
EP-0781766-A1 HETEROCYCLIC DERIVATIVE AND MEDICINE NIPPON SHINYAKU COMPANY, LIMITED (JP) 1997-07-02 EP claimed
EP-1941879-A1 Neuroprotective agent for the treatment of neuronal damage PAION Deutschland GmbH (DE) 2008-07-09 EP disclosed
US-20070021451-A1 Method for preventing or treating neurologic damage after spinal cord injury HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE (JP) 2007-01-25 US disclosed
EP-0781766-B1 HETEROCYCLIC DERIVATIVE AND MEDICINE NIPPON SHINYAKU CO LTD (JP) 2004-03-31 EP disclosed
US-6191149-B1 DRUG FOR CEREBROVASCULAR DISEASE NIPPON SHINYAKU, CO., LTD. (JP) 2001-02-20 US disclosed
US-5945426-A PREVENT NEURONAL DEATH NIPPON SHINYAKU CO., LTD. (JP) 1999-08-31 US disclosed
EP-0781766-A1 HETEROCYCLIC DERIVATIVE AND MEDICINE NIPPON SHINYAKU COMPANY, LIMITED (JP) 1997-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021451-A1 Method for preventing or treating neurologic damage after spinal cord injury SMN1; SMN2, AQP4, GAP43 KCNH2 1810/4885HRH3 3019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.